NovoCure NVCR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$173.05M-27.0% | -$136.23M+23.3% | -$177.65M-3.9% | -$170.95M-4.1% | -$164.19M+2.6% | ||
| $15.45M+5.5% | $14.65M+8.2% | $13.54M+9.8% | $12.33M+5.0% | $11.75M+4.5% | ||
| $138.29M+31.9% | $104.83M-29.1% | $147.77M-1.4% | $149.82M-3.7% | $155.5M-2.8% | ||
| $3.3M-31.9% | $4.85M+47.4% | $3.29M-6.3% | $3.51M+8.8% | $3.23M+178% | ||
| $4.51M-20.5% | $5.67M+2,176% | $249K+133% | -$760K+76.8% | -$3.28M-27.6% | ||
| $30.26M+59.6% | $18.96M-38.6% | $30.87M+129% | $13.49M-35.6% | $20.93M+9.6% | ||
| $7M+41.5% | $4.95M+32.9% | $3.73M+116% | $1.72M+138% | -$4.54M-598% | ||
| -$10.31M+4.9% | -$10.85M-67.4% | -$6.48M-9.9% | -$5.9M+37.1% | -$9.37M-17.6% | ||
| -$6.99M-32.5% | -$5.27M-36.6% | -$3.86M-30.1% | -$2.97M+48.1% | -$5.72M+10.1% | ||
| -$19.23M+17.4% | -$23.26M+11.2% | -$26.19M+1.3% | -$26.52M+1.5% | -$26.92M-5.0% | ||
| -$26.88M+45.2% | -$49.03M-42.2% | -$34.48M+22.8% | -$44.68M-46.7% | -$30.46M-15.5% | ||
| $21.19M-20.5% | $26.65M-13.2% | $30.69M-14.1% | $35.72M-14.3% | $41.68M-2.7% | ||
| $1.28B-0.8% | $1.29B+43.6% | $895M-0.6% | $900M+40.6% | $640M-17.7% | ||
| $802.32M-2.3% | $821.08M+4.5% | $785.57M-7.2% | $846.78M-14.6% | $991.25M+13.2% | ||
| $451.5M+3.3% | $437.28M+455% | $78.74M+350% | $17.5M+104% | -$392.93M-180% | ||
| $99.98M0.0% | $99.98M0.0% | $99.98M— | $0-100% | $96.92M0.0% | ||
| $560.95M0.0% | $560.95M— | $0— | $0-100% | $12.91M0.0% | ||
| $3.66M0.0% | $3.66M-10.8% | $4.1M0.0% | $4.1M-1.2% | $4.15M0.0% | ||
| -$456.76M-1.2% | -$451.34M-507% | $110.84M+964% | $10.42M-89.1% | $95.35M+5.6% | ||
| —— | —— | $342K-24.2% | $451K+314% | $109K+163% | ||
| -$32.11M+48.8% | -$62.7M-140% | $155.44M+1,053% | -$16.31M+95.0% | -$327.93M-329% | ||
| $15.72M+17.3% | $13.41M+22.5% | $10.94M-1.1% | $11.06M+6.8% | $10.36M+34.3% | ||
| $21.83M-28.8% | $30.67M+7.1% | $28.65M-10.1% | $31.86M+24.8% | $25.52M+8.8% | ||
| -$19.23M+17.4% | -$23.26M+11.2% | -$26.19M+1.3% | -$26.52M+1.5% | -$26.92M-5.0% | ||
| $3.3M-31.9% | $4.85M+47.4% | $3.29M-6.3% | $3.51M+8.8% | $3.23M+178% | ||
| —— | —— | -$1.22M-815% | $171K-80.8% | $889K+292% | ||
| $29.5M-24.2% | $38.94M+18.5% | $32.85M+5.9% | $31.02M-2.1% | $31.69M+20.2% | ||
| $7M+41.5% | $4.95M+32.9% | $3.73M+116% | $1.72M+138% | -$4.54M-598% | ||
| -$6.99M-32.5% | -$5.27M-36.6% | -$3.86M-30.1% | -$2.97M+48.1% | -$5.72M+10.1% | ||
| $802.32M-2.3% | $821.08M+4.5% | $785.57M-7.2% | $846.78M-14.6% | $991.25M+13.2% | ||
| —— | —— | —— | —— | $0— | ||
| $2.08M+34.9% | $1.54M-36.9% | $2.45M+7.4% | $2.28M+0.1% | $2.27M-26.2% | ||
| $6.88M-76.6% | $29.37M+1.7% | $28.89M+7.1% | $26.97M+13.8% | $23.7M+4,698% | ||
| $21.83M-28.8% | $30.67M+7.1% | $28.65M-10.1% | $31.86M+24.8% | $25.52M+8.8% | ||
| -$48.07M+36.5% | -$75.68M-16.1% | -$65.17M+18.9% | -$80.4M-11.4% | -$72.14M-4.2% | ||
| -$48.07M+36.5% | -$75.68M-16.1% | -$65.17M+18.9% | -$80.4M-11.4% | -$72.14M-4.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does NovoCure generate?
- NovoCure (NVCR) generated -$26.9M in operating cash flow over the trailing twelve months.
- What is NovoCure's free cash flow?
- After $21.2M of capital expenditures, NovoCure's free cash flow was -$48.1M over the trailing twelve months, up 33.4% year over year.
- Where does NovoCure's cash flow data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
